Press Releases

Latest News & Events

    Investment Highlights

    Paradigm shifting immunotherapy For complex, unmet clinical need indications

    Macrophage reprogramming, unmet medical need indications
    Off-the-shelf, universal cell therapy for resetting macrophages back to their ”manufacturer settings”, and away from “disease settings”

    Advanced clinical-stage pipeline with promising phase 2a results

    Advanced clinical-stage pipeline
    Phase IIb macrophage reprogramming for sepsis; Phase II COVID-19 Phase Ib macrophage reprogramming for solid tumor scheduled for 2021

    Advanced clinical-stage pipeline with promising phase 2a results

    Short regulatory approval pathway
    Specialized regulation in Europe potentially enabling post-Phase II marketing approval in sepsis and COVID-19

    Short regulatory approval pathway FDA & EU orphan designations; Specialized life-threatening regulation in Europe potentially enabling post-Phase II marketing approval

    Multi-billion dollar underserved markets
    Sepsis | Solid Tumors | COVID-19 | ARDS

    Strong leadership Previously founded and managed PROLOR Biotech, sold For $560M; Signed partnership with Pfizer, $295 Million down payment

    Strong leadership
    Previously founded and managed PROLOR Biotech, a $560M exit event; Signed partnership with Pfizer, $295 Million down payment

    Cash balance $30 Million invested; Expected cash balance of 2.5 Years at closing, Next clinical milestone within 12 months

    Cash balance
    ~$60 million invested; Cash balance supporting multiple clinical milestones within 18-24 months; Funded through Q1 2023

    SEC Filings

    Date Form Description Download

    Corporate Governance

    Charter of the Audit Committee of the Board of Directors download
    Charter of the Compensation Committee of the Board of Directors download
    Code of Business Conduct and Ethics download
    Disclosure Policy download
    Employee Complaint Procedures for Accounting and Auditing Matters download
    Insider Trading Policy download
    Download our company overview

    Find out more

    14 Einstein St. Nes-Ziona, Israel, 7403618
    T +972.2.6708072  |  F +972.2.6708070
    info@enlivex.com